Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Wichita State have busted the brackets of would-be basketball prognosticators.
Here at The Motley Fool, we decided to stick with what we know -- trading our basketball picks in for stock picks. We formed our own bracket filled with the top big pharma and big biotech stocks in a winner-take-all tournament as determined by the collective intelligence of our CAPS community.
This Elite Eight matchup is a heavyweight bout between health care colossus Johnson & Johnson and diversified pharmaceutical giant Novartis . Watch and find out which stock gets eliminated and which will advance to the next round.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
The article Health Care's Elite Eight Stocks: Johnson & Johnson vs. Novartis originally appeared on Fool.com.Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.